This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Valeant Pharmaceuticals International Inc (VRX)

NYSE: Health Care

Company Income Statement
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Sales 5.77B 3.55B 2.46B 1.18B
Cost of Sales 1.70B 944.78M 664.04M 368.63M
Gross Operating Profit 4.07B 2.60B 1.80B 812.60M
Selling, General, and Administrative Expenses 1.54B 812.86M 584.31M 367.42M
Research & Development 156.78M 268.95M 174.89M 157.56M
Operating Income before D & A (EBITDA) 2.37B 1.52B 1.04B 287.63M
Depreciation & Amortization 2.11B 1.02B 620.60M 256.88M
Interest Income 8.02M 5.99M 4.08M 1.29M
Other Income - Net -75.81M -1.24M 21.98M -43.16M
Special Income / Charges -153.64M 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -470.14M 79.17M 315.04M -151.96M
Interest Expense 844.32M 473.40M 333.04M 84.31M
Pre-Tax Income -1.31B -394.23M -18.00M -236.26M
Income Taxes -450.78M -278.20M -177.56M -28.07M
Minority Interest 2.47M 0.00 0.00 0.00
Net Income From Continuing Operations -863.67M -116.02M 159.56M -208.19M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -863.67M -116.02M 159.56M -208.19M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -866.14M -116.02M 159.56M -208.19M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-195.20M 306.97M 290.19M -67.35M
Preferred Dividends
Net Income Available To Common -863.67M -116.02M 159.56M -208.19M
Basic EPS from Continuing Ops. -2.70 -0.38 0.52 -1.06
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -2.70 -0.38 0.52 -1.06
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -2.70 -0.38 0.52 -1.06
Basic Normalized Net Income/Share -0.61 1.01 0.95 -0.34
EPS fr Continuing Ops. -2.70 -0.38 0.49 -1.06
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -2.70 -0.38 0.49 -1.06
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -2.70 -0.38 0.49 -1.06
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-0.61 1.01 0.89 -0.34
Dividends Paid per Share 0.00 0.00 0.00 1.28
VRX News

VRX Valeant Pharmaceuticals International Inc

Analysts Ratings for VRX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 8 9 9
Moderate Buy 1 2 2 2
Hold 2 1 1 1
Moderate Sell 0 1 1 1
Strong Sell 0 0 0 0
GET VRX ANALYST REPORT

Brokerage Partners

VRX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs